FEATURED CONTENT

• EU To Measure Trial Results Reporting

  The EU will publish the share of trials in the Clinical Trials Information System (CTIS) that meet results-reporting requirements, with the first report expected before the end of 2026.

• Clinical Trial Starts Take Hit From 'Perfect Storm'

  Clinical trial initiations in 2025 declined 16% versus 2024, reflecting a convergence of regulatory upheaval, funding contractions, geopolitical tensions, and sweeping government restructuring.

• Enrollment Rates Remain Low But Stable

  Overall industry-sponsored patient trial enrollment posted a combined median enrollment rate (MER) of 0.37 patients per site per month in the 2022–25 period, remaining relatively stable year to year.

• In Search Of A Cure For Low Enrollment In Oncology Clinical Trials

  Delayed enrollment can cost oncology trials up to $250K per patient. Explore the barriers keeping patients out and practical ways to reach more of them faster.

• Time, Trust, And Clarity: Rethinking Breast Cancer Trial Recruitment

  Breast cancer trial recruitment faces narrow treatment windows, unclear communication, and uneven trust in information sources. Patients favor their treating physician, and one unexpected channel also earns their confidence.

• Addressing The Singular Challenges Of Obesity Trials

  Competition and complexity characterize the obesity trial environment, making patient recruitment doubly challenging. Starting early in the planning stage can help address any potential obstacles.

• Clinical Trial Evaluation And Referral Challenging For Physicians

  Physicians often encounter information gaps when evaluating clinical trials for patients. A recent survey indicates a fragmented, confusing trial information landscape that is difficult to navigate.

• NIH To Extend Plain Language Results Requirement To Funded Studies

  New draft policy may require plain-language result summaries for clinical research participants. See what's in scope and how to prepare.

• CTIS Results In The Spotlight

  A new study finds fewer than half of EU Clinical Trial Information System (CTIS) trials met results reporting requirements. The EMA is now watching more closely. Here’s what sponsors need to know.

• Digital Twins: From Protocol Design to Predictive Study Execution

  A growing generation of AI-enabled digital twin approaches offers a new path. Instead of treating the protocol as a static document, organizations can model it as a dynamic system.

• Obesity Clinical Trials: A Promising Research Landscape

  Obesity is a hot topic in the pharmaceutical industry, with GLP-1 drugs dominating the headlines. Globally, there are 5,189 obesity trials, of which 1,119 are planned or ongoing.

• The State Of The Clinical Development Race

  Every medicine reaching a patient has run a race from a crowded grid of candidates through the clinical development circuit to the market launch podium. Catch up on what’s in store for this season.

• Examining The New Look For Biotech

  According to a recent episode of Citeline’s podcast series, “Small Biotechs, Big Decisions,” biotech is developing a new look that is leaner and savvier when it comes to working with partners.

• How AI Is Revolutionizing Clinical Development

  Artificial intelligence is expanding from the preclinical phase of clinical trials into Phases I–III, where is it being used in protocol design, site selection, feasibility, and patient recruitment.

• Under Half Of CTIS Trials Met Results Reporting Requirements

  A first assessment of compliance on EU Clinical Trial Information System (CTIS) found fewer than half of European Phase II–IV drug trials legally required to post results fully complied on time.

• Subject Matter Experts Matter In Decision-Making

  Expert-led ontology and taxonomy practices help organize data into meaningful hierarchies, making it easier to connect diseases, drug targets, and strategic insights that support stronger decisions.

• Busy Quarter For Gene, Cell, RNA Therapies

  Explore how Q2 brought renewed momentum for gene, cell, and RNA therapies and grew confidence in the future of advanced medicine with rising approvals, expanding pipelines, and increased investment.

• Rapid Expansion Of Peptide And Nanobody Drug Conjugates

  Peptide and nanobody drug conjugates are gaining momentum, with 106 active programs identified globally. Learn more about the fast-evolving space for targeted drug delivery and competitive opportunities.

• The People Behind The Products: Madeline Naylor

  A clinician's personal story reveals why trial awareness gaps delay patients from finding life-changing care and how data and AI are closing that gap.

• TrialScope EXTRA Keynotes Address Data Ownership, Health Communication

  Can your regulatory and protocol strategies keep pace with evolving data ownership, disclosure, and AI requirements? Explore key compliance risks, protections, and practical solutions.